AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15946554
Drug: Hepatectomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1
Trial: 12742477
Drug: Sirolimus with
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus with low-dose Prograf
Trial: 12742477
Drug: Sirolimus with
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus with full-dose Prograf
Trial: 10388978
Drug: Insulin-treated patients
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-treated patients with two or more hypoglycemic episodes
Trial: 8840366
Drug: Interferon (IFN)‐α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN)‐α treatment
Trial: 1796238
Drug: Quinine 10
RxNorm normalized name: quinine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 10 mg/kg body weight once daily for 5 days
Trial: 6404290
Drug: Ro 15-1788
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-1788 200 mg
Trial: 17559458
Drug: Intraligamental lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamental lignocaine (2% lignocaine solution with adrenaline 1 : 80 000)
Trial: 15507811
Drug: Chiropractic or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic or physiotherapy treatment
Trial: 9632126
Drug: 15 mmol
RxNorm normalized name: dibasic potassium phosphate 15 MMOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mmol Mg daily for 3 months
Trial: 9632126
Drug: Increased plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased plasma Mg concentration
Trial: 7870633
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of anti-hypertensive therapy
Trial: 7870633
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of anti-hypertensive therapy
Trial: 20216533
Drug: Antibiotic combination
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic combination therapy (oral amoxicillin 1500 mg/day, tetracycline 1500 mg/day, metronidazole 750 mg/day)
Trial: 30121419
Drug: Rivaroxaban treatment
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban treatment
Trial: 11821266
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg
Trial: 23296694
Drug: Benznidazole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole 7.5 mg/kg in a single daily dose for 30 days (Group B)
Trial: 21362162
Drug: Ferroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferroquine (400 to 1,600 mg single dose; up to 800 mg repeated dose)
Trial: 20021991
Drug: Olanzapine/fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/fluoxetine combination (OFC)
Trial: 12087932
Drug: Patch subgroup
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch subgroup (EP)
Trial: 12087932
Drug: Patch subgroup
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch subgroup (VC)
Trial: 12087932
Drug: Gel subgroup
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel subgroup (VC)
Trial: 2014947
Drug: Propranolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol plus Is‐5‐Mn (40 mg twice a day)
Trial: 6185788
Drug: Medroxalol (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxalol (100-400 mg twice daily)
Trial: 6185788
Drug: Medroxalol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxalol + Hydrochlorothiazide (12.5 mg twice daily)
Trial: 19666658
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride tablets
Trial: 10330635
Drug: Topical eyedrop
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical eyedrop anesthesia
Trial: 8545141
Drug: Capsaicin cream
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin cream (0.075%) applied 4 times a day
Trial: 6280052
Drug: Placebo (polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (polyethylene glycol ointment)
Trial: 20683071
Drug: Lidocaine nasal
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine nasal spray
Trial: 29231321
Drug: Acupuncture-moxibustion periodic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture-moxibustion periodic therapy
Trial: 26212400
Drug: Rehabilitation Intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rehabilitation Intensity of Therapy Scale
Trial: 19060263
Drug: Initial medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial medicine or surgery
Trial: 16856702
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group training (10 daily sessions for 2 weeks, 3 series of 10 repetitions of flexi‐extension of the foot against an elastic band)
Trial: 15459610
Drug: Nicorandil (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (4 mg as a bolus injection followed by constant infusion at 8 mg/hour for 24 hours)
Trial: 3169754
Drug: Pivampicillin (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin (700 mg twice a day for 7 days)
Trial: 3169754
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg twice a day for 7 days)
Trial: 28677416
Drug: Open-loop using
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-loop using sensor-augmented pump therapy (open-loop SAP)
Trial: 12644414
Drug: Lactate in
RxNorm normalized name: lactate Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate in the prime solution
Trial: 12644414
Drug: Lactate free
RxNorm normalized name: Lactate free hemofiltration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate free prime solution
Trial: 26156073
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg once daily, titrated based on tolerability)
Trial: 24447434
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic treatment (observation)
Trial: 23145755
Drug: Bupivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 15 mg 0.5% (group 1)
Trial: 23145755
Drug: Levobupivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 15 mg 0.5% (group 2)
Trial: 28931055
Drug: Normothermic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic treatment
Trial: 29643159
Drug: Multivitamin supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplements containing 150 µg iodine
Trial: 21432621
Drug: Generic tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic tamsulosin sustained-release tablets (Prostam(®))
Trial: 16871060
Drug: Remifentanil (0-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0-15 ng/ml) and sevoflurane (0-6 vol%)
Trial: 16871060
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.75 vol% sevoflurane and 6.2 ng/ml remifentanil
Trial: 14680725
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day quinapril for 8 weeks
Trial: 10870853
Drug: 60 mcg
RxNorm normalized name: Aranesp 60 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mcg PGE1 daily given IV in 250 mL saline over a period of 2 hours (21 patients)
Trial: 10870853
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mL saline, 21 patients)
Trial: 25038064
Drug: MIRT Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIRT Group (two 28-day multidisciplinary intensive rehabilitation treatments at 1-year interval)
Trial: 25038064
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (only drug)
Trial: 18497611
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with intravenous morphine
Trial: 17361522
Drug: Compound Glycyrrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Glycyrrhizin Injection (CGI)
Trial: 26277872
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 1.0 μg/kg infused over 10 minutes, maintenance dose of 0.4 μg/kg per hour for 6 hours)
Trial: 23912692
Drug: Gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine alone (1,000 mg m(‐2))
Trial: 23912692
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus cisplatin (G + C) (1,000 mg m(‐2) gemcitabine and 25 mg m(‐2) cisplatin)
Trial: 20206795
Drug: Ticlopidine 250
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 250 mg alone
Trial: 7708953
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose distributions assessment in a separate group of 37 women
Trial: 3371023
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg iv every 6 h
Trial: 3371023
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg iv every 6 h
Trial: 1984813
Drug: Tetrahydroaminoacridine (THA)
RxNorm normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrahydroaminoacridine (THA) 50 to 100 mg daily
Trial: 6872413
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg amrinone
Trial: 27009515
Drug: Ranibizumab 'intensive'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 'intensive' treatment (complete resolution of IRF and SRF)
Trial: 27009515
Drug: Ranibizumab 'relaxed'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 'relaxed' treatment (resolution of IRF or >200 μm SRF only at foveal centre)
Trial: 27009515
Drug: Ranibizumab 'intensive'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 'intensive' treatment
Trial: 27009515
Drug: Ranibizumab 'relaxed'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 'relaxed' treatment
Trial: 20298591
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg SC enoxaparin
Trial: 20298591
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg SC enoxaparin
Trial: 20298591
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg SC enoxaparin
Trial: 12459658
Drug: Perflubron emulsion
RxNorm normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perflubron emulsion (1.8 g/kg, with an additional 0.9 g/kg dose if hemoglobin < 6.5 g/dl)
Trial: 20306820
Drug: Intravenous montelukast,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous montelukast, 5.25 mg
Trial: 15951475
Drug: Conventional dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional dipyridamole tablets (immediate-release)
Trial: 8273981
Drug: Aspirin 2600
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 2600 mg/d
Trial: 8273981
Drug: Aspirin 3
RxNorm normalized name: aspirin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 3 mg/d
Trial: 8273981
Drug: Aspirin 10
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 10 mg/d
Trial: 27789385
Drug: Nocebo suggestions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocebo suggestions (suggestions of pain increase with nocebo cream)
Trial: 27789385
Drug: Placebo suggestions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suggestions (suggestions of pain decrease with placebo cream)
Trial: 27789385
Drug: Natural history
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural history group (no treatment)
Trial: 16492702
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate (267 mg/d)
Trial: 8829419
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 5 mg (10 patients)
Trial: 8829419
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine 5 mg (10 patients)
Trial: 1625092
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hGH plus oxandrolone
Trial: 1625092
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with hGH (both alone and in combination with oxandrolone)
Trial: 6548095
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of methohexitone (5 mg/kg)
Trial: 6548095
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of methohexitone (25 mg/kg)
Trial: 6548095
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of methohexitone (2 mg/kg)
Trial: 6548095
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of pharmacokinetics in children vs adults
Trial: 30316811
Drug: Daily Undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Undulating Periodization (NLP)
Trial: 25319729
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day aqueous saffron extract orally
Trial: 23007147
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 8 mg/m² (day 1) and Vinorelbine (VNR) 25 mg/m² (days 1 and 8) every 4 weeks for up to 6 cycles
Trial: 17445831
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR 150 mg/day
Trial: 15905675
Drug: TMC114/ritonavir (RTV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC114/ritonavir (RTV) (300/100 mg or 600/100 mg twice daily, or 900/100 mg once daily)
Trial: 12506950
Drug: Fluconazole suspension
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole suspension 3 mg/kg in a single daily dose for 7 days
Trial: 12506950
Drug: Nystatin oral
RxNorm normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nystatin oral suspension four times a day for 10 days
Trial: 2705441
Drug: Subcutaneous DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous DDAVP
Trial: 2705441
Drug: Intravenous DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous DDAVP
Trial: 335794
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beta-receptor blocker and hydralazine (regimen B)
Trial: 11441208
Drug: High-dose acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acetaminophen (1000 mg)
Trial: 11441208
Drug: Low-dose acetaminophen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetaminophen (500 mg)
Trial: 8332152
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment with ceftriaxone (50 mg/kg body weight, initial dose followed by a second dose 24 hours later)
Trial: 8332152
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (ceftriaxone as directed by physicians)
Trial: 30882476
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (crystalloid)
Trial: 21246578
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish treatment
Trial: 17349686
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri ATCC 55730 (1 x 10(8) colony forming units) daily from gestational week 36 until delivery and continued from birth until 12 months of age.
Trial: 17349686
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (not specified dosage or duration).
Trial: 12960597
Drug: Follow-up 201Tl‐chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up 201Tl‐chloride scintigraphy after chemotherapy
Trial: 10824635
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion after pretreatment with nadolol or propranolol
Trial: 10824635
Drug: Propranolol (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (doses < or =7.5 mg)
Trial: 1430708
Drug: Inhaled indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled indomethacin (25 mg and 50 mg)
Trial: 6539002
Drug: Stanozolol 50
RxNorm normalized name: stanozolol 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanozolol 50 mg intramuscularly 24 hr before surgery
Trial: 3524929
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 240 mg orally for 12 weeks
Trial: 29046302
Drug: Tea administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea administered simultaneously with the meal (TM-2)
Trial: 29046302
Drug: Tea administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea administered 1 hour postmeal (TM-3)
Trial: 29046302
Drug: Water administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water administered with the meal (TM-1)
Trial: 14694916
Drug: Air (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air (5 L/min)
Trial: 10869641
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine (2 mg, dose-optimization schedule)
Trial: 10869641
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine (5 mg, fixed-dose)
Trial: 10869641
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine (6 mg, fixed-dose)
Trial: 10869641
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine (all doses)
Trial: 1607415
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% cream, applied twice daily for 1 week
Trial: 4026357
Drug: Frusemide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (1 mg/kg) administered intravenously at approximately 24 hour intervals for three doses.
Trial: 24305905
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support workers (PSWs) trained over 12 weekly, 1-day sessions from April to July 2010.
Trial: 10502583
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin
Trial: 16231265
Drug: 28-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 28-day regimen of antiretroviral therapy and counseling